Semaglutide, marketed under the brand names Ozempic, Wegovy, and Rybelsus, is a GLP-1 agonist available in various forms, including weekly injections (Ozempic for diabetes and Wegovy for obesity) and daily oral tablets (Rybelsus)
As such, they may overlook symptoms that individuals find bothersome but less dangerous, or that occur less frequently
Candidates must be in good health overall, not have any medical conditions that are out of control, and have kept their weight consistent
Your provider may recommend: Reviewing nutrition basics (protein, fiber, hydration) Adjusting habits and activity goals Updating dosage or timing when appropriate Checking sleep and stress factors The goal is sustainable progress, not extreme restriction